Feasibility of administering anti-CD45 iodine ((131)I) apamistamab [Iomab-B] for targeted conditioning in older patients with active, relapsed or refractory AML without lead-lined rooms: Ongoing phase III SIERRA trial experience at 6 study sites Meeting Abstract
| Authors: | Nath, R.; Chu, B.; Chen, L.; Sadeghi, A.; Senglaub, T.; Kaiser, L.; Saganich, C.; Zgaljardic, M.; Rutar, F.; Harling, S.; Liang, Q.; Hari, P.; van Besien, K.; Al-Kadhimi, Z.; Schuster, M. W.; Reddy, V.; Berger, M. S.; Konerth, S.; Liverett, M.; Gyurkocza, B. |
| Abstract Title: | Feasibility of administering anti-CD45 iodine ((131)I) apamistamab [Iomab-B] for targeted conditioning in older patients with active, relapsed or refractory AML without lead-lined rooms: Ongoing phase III SIERRA trial experience at 6 study sites |
| Meeting Title: | Transplantation and Cellular Therapy Meetings of ASBMT and CIBMTR |
| Journal Title: | Biology of Blood and Marrow Transplantation |
| Volume: | 26 |
| Issue: | 3 Suppl. |
| Meeting Dates: | 2020 Feb 19-23 |
| Meeting Location: | Orlando, FL |
| ISSN: | 1083-8791 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2020-03-01 |
| Start Page: | S198 |
| End Page: | S199 |
| Language: | English |
| ACCESSION: | WOS:000516887900290 |
| PROVIDER: | wos |
| DOI: | 10.1016/j.bbmt.2019.12.687 |
| Notes: | Meeting Abstract: 291 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
